Is that why Immutep Limited (NASDAQ: IMMP) is booming and glooming in the Post-market hours?

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

Immutep Limited (NASDAQ: IMMP) stock surged 62% to touch $3.4 in the late-hours trading after, a biotech company that explores novel immunotherapy therapies for cancer and autoimmune diseases, confirmed report that EOC Pharma, its Chinese partner, will launch a new Phase II clinical trial in China for up to 152 patients with metastatic breast cancer.

A randomized, double-blind, placebo-controlled phase II clinical study with study endpoints like progression-free survival, overall survival, and overall response rate would be the EOC Pharma trial, close to Immutep’s AIPAC study. It is planned to take place across 24 months across 20 clinical trial sites in China and test Immutep’s lead candidate medication eftilagimod alpha in conjunction with paclitaxel in patients with HER2-negative/HR-positive metastatic breast cancer who have progression following endocrine therapy.

The Chinese authoritative body, the Chinese National Medical Goods Administration, has obtained positive technical guidance from EOC Pharma, causing the first patient to be enrolled and dosed in the trial in Q1 of the calendar year 2021.

Leave a Comment

Your email address will not be published.

Latest Posts